BRIEFCASE | SEARCH | EMAIL THIS EVENT | LOGIN    
RSNA 2003 Scientific Papers > Large-sized Hepotocellular Carcinoma (HCC): Neoadjuvant ...
 
  Scientific Papers
  SESSION: Vascular Interventional (Interventions)

Large-sized Hepotocellular Carcinoma (HCC): Neoadjuvant Treatment Protocol with Repetitive Transarterial Chemoembolization (TACE) before Percutaneous MR-guided Laser-induced Thermotherapy (LITT)

  DATE: Tuesday, December 02 2003
  START TIME: 03:00 PM
  END TIME: 03:07 PM
  LOCATION: Room E451B
  CODE: J10-793
TOOLS
 
ADD TO BRIEFCASE
  PRINT
  EMAIL

PARTICIPANTS
PRESENTER
Stefan Zangos MD
Frankfurt/Main Germany
 
CO-AUTHOR
Joern Balzer MD
 
Martin Mack MD
 
Katrin Eichler MD
 
Oliver Soellner MD
 
Thomas Vogl MD
 

MOC
Vascular And/or Interventional
Keywords
Hepatic arteries, chemotherapeutic embolization
Liver, interventional procedures
Liver neoplasms, therapeutic radiology
 
Abstract:
HTML

Purpose: To evaluate the feasibility and efficacy of the therapeutic approach of repeated transarterial chemoembolization (TACE) before MR-guided LITT (laser induced thermotherapy) for large sized hepatocellular carcinomas (HCC).

Methods and Materials: Repeated TACE were performed in 100 patients with hepatocellular carcinoma using 10 mg/m2 mitomycin, 10 ml/m2 lipiodol and microspheres. A total number of 424 TACE (mean: 4.2 treatments per patient) was performed in all patients. The tumor volume was measured by MR-imaging. Lipiodol retention and perfusion of the tumors were evaluated by CT and angiography. Within 4-6 weeks after documentation of response to the TACE treatment MR-guided LITT followed.

Results: In 87 patients a high lipiodol retention in the tumor after TACE was observed. There were no major complications induced by TACE and the observed Side effects after TACE were moderate. Repeated TACE enabled a reduction in tumor size and tumor perfusion in 22 patients, forming the basis for the performance of MR-guided LITT procedure for a complete ablation of the tumor. These patients received 2 to 6 TACE (mean: 3.2 treatment per patient) treatments followed by 2 to 4 (mean: 3.3) laser treatments. The median survival period after the first TACE treatment was with 18.71 months for the palliative group and statistically significant higher with 39.76 months in the neoadjuvant group.

Conclusion: Repeated TACE treatment appears to be an safe and effective treatment of large HCC with the additional potential of neoadjuvant intention before MR-guided LITT.

 

 

 


Questions about this event email: Zangos@em.uni-frankfurt.de